8-K: NeueHealth Secures $150 Million Loan Facility with Hercules Capital

NeueHealth has secured a loan facility of up to $150 million with Hercules Capital to support its strategic priorities and strengthen its capital position.

Summary

• NeueHealth has entered into a loan and security agreement with Hercules Capital for up to $150 million.
• The loan is structured in four tranches, with an initial $30 million available immediately.
• A second tranche of $25 million is available between November 10, 2024, and December 31, 2024, contingent on certain conditions related to a stock purchase agreement with Molina Healthcare.
• A third tranche of $45 million is available between February 5, 2025, and September 15, 2025, subject to the company meeting certain payment obligations and maintaining at least $22.5 million in unrestricted cash.
• A fourth tranche of up to $50 million is available until June 21, 2027, upon further approval by the lenders.
• The loan accrues interest at a rate of the greater of the Wall Street Journal Prime Rate plus 1.15% or 9.65%, plus an additional 2.50% payable in kind.
• The loans mature on June 1, 2028, with no amortization payable until June 1, 2027.
• The company may prepay the loans with fees ranging from 1% to 3% depending on the timing of the prepayment.
• The agreement includes covenants requiring the company to maintain at least $15 million in qualified cash and meet certain adjusted EBITDA targets.
• The company also issued warrants to the lenders, allowing them to purchase up to 1,250,000 shares of common stock at $0.01 per share.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the new financing and its potential to support the company's growth. However, the document also includes standard risk disclosures and financial covenants, which temper the overall sentiment.

Positives

• The $150 million loan facility provides NeueHealth with significant capital to support its strategic priorities.
• The financing strengthens the company's capital position, allowing it to focus on delivering value-driven care.
• The loan facility is structured in tranches, providing flexibility in accessing funds as needed.
• The company has established relationships with payors, providers, and consumers across the industry.
• The company's value-driven, consumer-centric care model is seen as a potential transformation of the healthcare experience.

Negatives

• The loan agreement includes covenants that restrict the company's ability to make certain cash dividends, incur additional debt, and engage in certain transactions.
• The company is subject to prepayment fees if it chooses to pay off the loan early.
• The interest rate is variable and tied to the Wall Street Journal Prime Rate, which could increase the cost of borrowing.
• The company must meet certain financial conditions to access the second and third tranches of the loan.

Risks

• The company's ability to continue as a going concern is a risk factor.
• The company's ability to comply with the terms of the credit facilities is a risk.
• The company's ability to receive the remaining proceeds from the sale of its Medicare Advantage business in California in a timely manner is a risk.
• The company's ability to obtain any short or long term debt or equity financing needed to operate its business is a risk.
• The company's ability to quickly and efficiently complete the wind down of its remaining IFP and MA businesses is a risk.
• Potential disruptions to the company's business due to corporate restructuring and any resulting headcount reduction is a risk.
• The company's ability to accurately estimate and effectively manage the costs relating to changes in its businesses offerings and models is a risk.
• A delay or inability to withdraw regulated capital from the company's subsidiaries is a risk.
• A lack of acceptance or slow adoption of the company's business model is a risk.
• The company's ability to retain existing consumers and expand consumer enrollment is a risk.
• The company's and its care partners abilities to obtain and accurately assess, code, and report risk adjustment factor scores is a risk.
• The company's ability to contract with care providers and arrange for the provision of quality care is a risk.
• The company's ability to obtain claims information timely and accurately is a risk.
• The impact of any pandemic or epidemic on the company's business and results of operations is a risk.
• The risks associated with the company's reliance on third-party providers to operate its business is a risk.
• The impact of modifications or changes to the U.S. health insurance markets is a risk.
• The company's ability to manage any growth of its business is a risk.
• The company's ability to operate, update or implement its technology platform and other information technology systems is a risk.
• The company's ability to retain key executives is a risk.
• The company's ability to successfully pursue acquisitions and integrate acquired businesses is a risk.
• The occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest is a risk.
• The company's ability to prevent and contain data security incidents and the impact of data security incidents on its members, patients, employees and financial results is a risk.
• The company's ability to comply with requirements to maintain effective internal controls is a risk.
• The company's ability to adapt to mitigate risks associated with its ACO Reach businesses, including any unanticipated market or regulatory developments is a risk.

Future Outlook

The company intends to use the financing to support its strategic priorities in 2024 and beyond, focusing on delivering value-driven, consumer-centric care. The company also plans to file the Loan and Security Agreement and the Warrant Agreements with the SEC as exhibits to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.

Management Comments

• Mike Mikan, President and CEO of NeueHealth, stated that the financing puts the company in a strong position to advance its differentiated care model.
• Tom Hertzberg, Managing Director at Hercules, expressed pleasure in supporting NeueHealth and sees significant opportunities in the company's ability to drive value for payors and providers.
• Mike McMahon, Director at Hercules, added that NeueHealth is driving value in healthcare for all and they are thrilled to be their financial partner.

Industry Context

This announcement comes as the healthcare industry continues to shift towards value-based care models. NeueHealth's focus on aligning the interests of health consumers, providers, and payors positions it to capitalize on this trend. The financing will enable the company to further develop its care model and expand its reach in the ACA Marketplace, Medicare, and Medicaid.

Comparison to Industry Standards

• The loan facility with Hercules Capital is a common financing method for growth-stage healthcare companies.
• The interest rate and terms are typical for secured debt financing in the current market.
• The inclusion of warrants is a standard practice in venture debt financing, providing lenders with potential upside in the company's equity.
• Companies like Oak Street Health and Agilon Health have also utilized debt financing to support their growth strategies, although the specific terms and conditions may vary.
• The focus on value-based care aligns with industry trends, with companies like CareMore and Iora Health also pursuing similar models.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the warrants issued to the lenders.
• Employees may benefit from the company's improved financial position and growth prospects.
• Customers may experience improved services and care as the company invests in its strategic priorities.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• The company will file the Loan and Security Agreement and the Warrant Agreements with the SEC as exhibits to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
• The company will continue to execute its strategic priorities using the new financing.
• The company will need to meet certain financial conditions to access the second and third tranches of the loan.

Key Dates

Keywords

Loan Facility, Hercules Capital, Healthcare Financing, Term Loan, Warrants, Debt Financing, Value-Based Care, NeueHealth, Healthcare